Researcher
Thierry VandenDriessche
- Keywords (Vrije Universiteit Brussel):Medicine, Applied biological sciences, biotechnology
- Disciplines (Vrije Universiteit Brussel):Hematology, Neurological and neuromuscular diseases, Cancer therapy, Cardiology, Computational transcriptomics and epigenomics
- Disciplines (KU Leuven):Gene and molecular therapy
- See also: Thierry Vandendriessche (KU Leuven)
Affiliations
- Division of Gene Therapy & Regenerative Medicine (Research group)
Responsible
From19 Apr 2011 → Today - Basic (bio-) Medical Sciences (Department)
Member
From8 Apr 2019 → Today - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Cell Biology and Histology (Department)
Member
From1 Oct 2010 → 31 Dec 2013 - Department of Bio-engineering Sciences (Department)
Member
From1 Feb 2010 → 28 Feb 2010 - Immunology and Microbiology (Department)
Member
From1 Oct 2007 → 30 Sep 2010 - Department of Bio-engineering Sciences (Department)
Member
From1 Feb 2007 → 30 Sep 2010 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2003 → 30 Sep 2004 - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → Today - Department of General Biology (Research group)
Member
From1 Oct 1990 → 30 Sep 1994
Projects
11 - 17 of 17
- Development of non-viral gene therapy for hemophilia with innovative hyperactive transposon technologyFrom1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- miRNA modulation in cancer with the help of designer Transcription Activator-Like Effector Nucleases (TALENs): a new platform for oncological researchFrom1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- IOF proof of Concept: Clinical translation of gene therapy for hemophilia, consolidation of a spin-off companyFrom1 Nov 2013 → 31 Oct 2015Funding: IOF - Industrial Research Fund
- Cardiovascular and muscle-specific "targeting" for gene therapy of neuromuscular disordersFrom1 Jan 2013 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Immune stealth nanotechnology for gene therapy of hemophilia 'A': mechanisms and translational implicationsFrom1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- Myotonic dystrophy type 1 (DM1)-specific induced pluripotent stem cells (iPS): an innovative platform for myogenic and cardiomyogenic differentiation and validation of novel therapeutic approachesFrom1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- Interplay between Epigenetic Modification Mechanisms and microRNAs - EPIGENFrom1 Jan 2011 → 31 Dec 2015Funding: BOF - Concerted Research Project from 1994
Publications
1 - 10 of 70
- Treatment of Infantile-Onset Pompe Disease in a Rat Model with Muscle-Directed AAV Gene Therapy(2024)
Authors: Sergio Muñoz, Joan Bertolin, Veronica Jimenez, Maria Luisa Jaén, Miquel Garcia, Anna Pujol, Laia Vilà, Victor Sacristan, Elena Barbon, Giuseppe Ronzitti, et al.
- Hemophilia Gene Therapy(2023)
Authors: Dries De Wolf, Kshitiz Singh, Marinee K Chuah, Thierry VandenDriessche
Pages: 782-792 - Hemophilia "A" gene therapy(2022)
Authors: Thierry VandenDriessche, Marinee K Chuah
Pages: 3508-3509 - Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy(2022)
Authors: Jaitip Tipanee, Ermira Samara-Kuko, Thierry Gevaert, Marinee K Chuah, Thierry VandenDriessche
Pages: 3155-3175 - Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders(2022)
Authors: Jihad El Andari, Edith Renaud-Gabardos, Warut Tulalamba, Jonas Weinmann, Louise Mangin, Quang Hong Pham, Susanne Hille, Antonette Bennett, Esther Attebi, Emanuele Bourges, et al.
- Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes(2022)
Authors: Sumitava Dastidar, Debanjana Majumdar, Jaitip Tipanee, Kshitiz Singh, Arnaud F. Klein, Denis Furling, Marinee K Chuah, Thierry VandenDriessche
Pages: 75-91 - The RNA World(2021)
Authors: Thierry Vandendriessche
Pages: 975-977 - Dose-dependent microdystrophin expression enhancement in cardiac muscle by a cardiac specific regulatory element(2021)
Authors: Alberto Malerba, Chiara Sidoli, Ngoc B Lu-Nguyen, Shanthi Herath, Anita Le Heron, Hayder Abdul-Razak, Susan Jarmin, Thierry VandenDriessche, Marinee K Chuah, George Dickson, et al.
Pages: 1138-1146 - Gene Therapy For Hemophilia B Using CB 2679d-GT: A Novel Factor IX Variant With Higher Potency Than Factor IX Padua(2021)
Authors: Nisha Nair, Dries De Wolf, Phuong Anh Nguyen, Hong Quang Pham, Ermira Samara-Kuko, Jeff Landau, Grant E.Blouse, Marinee K Chuah, Thierry VandenDriessche
Pages: 2902-2906 - Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants(2020)
Authors: Jonas Weinmann, Sabrina Weis, Josefine Sippel, Warut Tulalamba, Anca Remes, Jihad El Andari, Anne-Kathrin Herrmann, Hong Quang Pham, Christopher Borowski, Susanne Hille, et al.
Patents
1 - 10 of 10
- Vectors for liver-directed gene therapy of hemophilia and methods and use thereof (Inventor)
- Muscle-specific nucleic acid regulatory elements and methods and use thereof (Inventor)
- Optimized liver-specific expression systems for fviii and fix (Inventor)
- Novel combination of nucleic acid regulatory elements and methods and uses thereof (Inventor)
- Novel combination of nucleic acid regulatory elements and methods and uses thereof (Inventor)
- Vector for liver-directed gene therapy of hemophilia and methods and use thereof (Inventor)
- Muscle-specific nucleic acid regulatory elements and methods and use thereof (Inventor)
- Endothelium-specific nucleic acid regulatory elements and methods and use thereof (Inventor)
- Cardiomyocyte-derived nucleic acid regulatory elements and methods and use thereof (Inventor)
- Vector for liver-directed gene therapy of hemophilia and methods and use thereof (Inventor)